These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

793 related items for PubMed ID: 17059510

  • 1. Review article: Medical therapy for fistulizing Crohn's disease.
    Bressler B, Sands BE.
    Aliment Pharmacol Ther; 2006 Nov 01; 24(9):1283-93. PubMed ID: 17059510
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.
    Egan LJ, Sandborn WJ, Tremaine WJ.
    Am J Gastroenterol; 1998 Mar 01; 93(3):442-8. PubMed ID: 9517654
    [Abstract] [Full Text] [Related]

  • 4. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 5. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.
    Dig Liver Dis; 2005 Jun 01; 37(6):407-17. PubMed ID: 15893279
    [Abstract] [Full Text] [Related]

  • 6. Clinical outcome of Crohn's disease treated with infliximab.
    Arslan S, Kav T, Besisik F, Kaymakoglu S, Pinarbasi B, Tözün N, Hamzaoglu HO, Duman D, Ulker A, Parlak E, Palabiyikoglu M, Dökmeci A.
    Hepatogastroenterology; 2003 Jun 01; 50(52):952-6. PubMed ID: 12845957
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Infliximab in fistulizing Crohn's disease.
    Osterman MT, Lichtenstein GR.
    Gastroenterol Clin North Am; 2006 Dec 01; 35(4):795-820. PubMed ID: 17129814
    [Abstract] [Full Text] [Related]

  • 9. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P, Zwolińska-Wcisło M, Przybylska M, Mach T.
    Przegl Lek; 2011 Dec 01; 68(9):602-5. PubMed ID: 22335009
    [Abstract] [Full Text] [Related]

  • 10. Review article: treatment of perianal fistulizing Crohn's disease.
    Rutgeerts P.
    Aliment Pharmacol Ther; 2004 Oct 01; 20 Suppl 4():106-10. PubMed ID: 15352905
    [Abstract] [Full Text] [Related]

  • 11. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM, Krauss N, Voll RE, Nägel A, Weidenhiller M, Konturek PC, Hahn EG, Raithel M.
    Digestion; 2008 Oct 01; 78(4):195-200. PubMed ID: 19122456
    [Abstract] [Full Text] [Related]

  • 12. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ, Hanauer SB.
    Am J Gastroenterol; 2002 Dec 01; 97(12):2962-72. PubMed ID: 12492177
    [Abstract] [Full Text] [Related]

  • 13. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.
    Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ.
    Aliment Pharmacol Ther; 2006 Apr 15; 23(8):1127-36. PubMed ID: 16611273
    [Abstract] [Full Text] [Related]

  • 14. Infliximab use in luminal Crohn's disease.
    Richter JA, Bickston SJ.
    Gastroenterol Clin North Am; 2006 Dec 15; 35(4):775-93. PubMed ID: 17129813
    [Abstract] [Full Text] [Related]

  • 15. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease.
    Sandborn WJ.
    Am J Gastroenterol; 1997 May 15; 92(5):876-9. PubMed ID: 9149205
    [Abstract] [Full Text] [Related]

  • 16. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.
    Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ.
    Am J Gastroenterol; 2001 Mar 15; 96(3):722-9. PubMed ID: 11280541
    [Abstract] [Full Text] [Related]

  • 17. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
    Lindsay J, Punekar YS, Morris J, Chung-Faye G.
    Aliment Pharmacol Ther; 2008 Jul 15; 28(1):76-87. PubMed ID: 18410558
    [Abstract] [Full Text] [Related]

  • 18. Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin.
    Prantera C, Berto E, Scribano ML, Falasco G.
    Ital J Gastroenterol Hepatol; 1998 Dec 15; 30(6):602-6. PubMed ID: 10076781
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Review article: chronic active disease and maintaining remission in Crohn's disease.
    Kamm MA.
    Aliment Pharmacol Ther; 2004 Oct 15; 20 Suppl 4():102-5. PubMed ID: 15352904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.